Guardant Health, Inc. announced a strategic partnership with PathGroup, a leading partner to physicians, hospitals, and healthcare networks. This collaboration will significantly expand the reach of Guardant’s FDA-approved Shield blood test for colorectal cancer screening.
The partnership will bring Shield to over 250 hospitals and health systems and more than 15,000 PathGroup-affiliated physicians across 25 states. PathGroup, which serves over five million patients annually, will integrate Shield into its electronic ordering systems, ensuring a frictionless ordering experience.
AmirAli Talasaz, Guardant Health co-CEO, stated that this partnership is an important milestone in bringing the convenient screening option of Shield to as many people as possible and accelerating commercial distribution. The collaboration aims to reach millions of patients who might otherwise face barriers to screening, and PathGroup will also provide expertise in immunohistochemistry (IHC) testing for Guardant.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.